Colorectal cancer (CRC) is the third most frequent malignant tumor in the world, placing a heavy burden on global health due to its rising frequency. By 2040, the burden of CRC was projected to increase by 63%, reaching 1.6 million deaths, with some 80% expected to occur in countries with a high level of human development index, it is the second most common cause of cancer death. 30% of stage II and 50%–60% of stage III colorectal cancer patients are reported to experience recurrence within 5 years of treatment. There have been significant improvements in oncologic outcomes in stage II–III colorectal cancer over the past decades as a result of the development of surgical techniques and adjuvant therapy.
Early identification helps lower the incidence and death of CRC since precancerous lesions give rise to the disease slowly. CRC can be broadly divided into two groups, one of which is heritable and the other sporadic. Colonoscopy remains the most common diagnostic technique after an individual present with CRC symptoms. However, the slow nature of the precancerous lesions suggests a molecular diagnostic method can result in earlier treatment. In order to aid patients who present with the most severe forms of CRC, improvements in molecular genetics and therapies of CRC have continued to delve into understanding the molecular mechanisms of CRC. It is thought that a series of genetic alterations lead to CRC therefore, mass screening and early intervention could help diagnose CRC at an earlier stage and lower the chance of mortality from the condition. There is an urgent need for molecular diagnosis of Colorectal Cancer.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advances in genetics and molecular diagnosis in Colorectal Cancer.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Colorectal cancer (CRC) is the third most frequent malignant tumor in the world, placing a heavy burden on global health due to its rising frequency. By 2040, the burden of CRC was projected to increase by 63%, reaching 1.6 million deaths, with some 80% expected to occur in countries with a high level of human development index, it is the second most common cause of cancer death. 30% of stage II and 50%–60% of stage III colorectal cancer patients are reported to experience recurrence within 5 years of treatment. There have been significant improvements in oncologic outcomes in stage II–III colorectal cancer over the past decades as a result of the development of surgical techniques and adjuvant therapy.
Early identification helps lower the incidence and death of CRC since precancerous lesions give rise to the disease slowly. CRC can be broadly divided into two groups, one of which is heritable and the other sporadic. Colonoscopy remains the most common diagnostic technique after an individual present with CRC symptoms. However, the slow nature of the precancerous lesions suggests a molecular diagnostic method can result in earlier treatment. In order to aid patients who present with the most severe forms of CRC, improvements in molecular genetics and therapies of CRC have continued to delve into understanding the molecular mechanisms of CRC. It is thought that a series of genetic alterations lead to CRC therefore, mass screening and early intervention could help diagnose CRC at an earlier stage and lower the chance of mortality from the condition. There is an urgent need for molecular diagnosis of Colorectal Cancer.
For this Research Topic, we welcome submissions of Original Research and Reviews highlighting the advances in genetics and molecular diagnosis in Colorectal Cancer.
Please note: manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
